NCT01089751

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 322 (actual)
• Sponsor: Allergan · Industry
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	trospium chloride	Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
DRUG	placebo	Placebo once daily on an empty stomach for 14 weeks.

Timeline

• Start date: 2010-03-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2010-03-19
• Last updated: 2013-09-26
• Results posted: 2013-09-26

Locations

1 site across 1 country: United States